Pharmaceutical compound containing silymarin and carbopol, its manufacturing process and its use as a regenerator of the pancreatic tissue and cells of endogenous secretion damaged by diabetes mellitus
The present invention refers to a new compound containing Silymarin with Carbopol for the treatment of Diabetes Mellitus. This compound morphologically and structurally regenerates the damage that occurs in the pancreatic tissue in Diabetes Mellitus, and regenerates the insulin-producing pancreatic cells (β cells). It therefore regulates the serum levels of this hormone. Furthermore, it restores and maintains the normal concentrations of the blood glucose.
